Intravitreal anti-VEGF injections are a mainstay of treatment for retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion, and usually require repeated administration over years. During each injection an eyelid speculum holds the lids open and the upper eyelid is exposed to repeated mechanical stretch. Aponeurotic ptosis after intraocular surgery is well described, but evidence on blepharoptosis after repeated intravitreal injections is limited and conflicting.
This single-center prospective observational study enrolls 60 patients who are starting intravitreal anti-VEGF therapy in one eye only; the untreated fellow eye of each patient serves as an internal control. Upper eyelid position and function are assessed with margin reflex distance-1 (MRD-1), margin reflex distance-2 (MRD-2) and levator function at baseline and at months 1, 3 and 6. The primary endpoint is the difference between the injected eye and the fellow eye in the change in MRD-1 from baseline to month 6.

Start Date25 Sep 2026

Sponsor / Collaborator

Fatih Sultan Mehmet Training and Research Hospital

NCT07812090

/ RecruitingPhase 2

A Randomized, Double-Masked, Multicenter Phase 2 Study Evaluating the Efficacy, Safety, and Tolerability of Oral BGE-102 as Mono- and Combination Therapy in Participants With Center-Involved Diabetic Macular Edema

The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME). BGE-102 decreases inflammation which may improve vision or slow the progression of vison loss in those with CI-DME. Participants will be randomized to one of 3 arms and receive either BGE-102 in combination with an anti-vascular endothelial growth factor (anti-VEGF) drug, BGE-102 in combination with sham injection, or BGE-102 placebo in combination with an anti-VEGF drug. This study will also evaluate safety and tolerability of BGE-102.

Start Date21 Aug 2026

Sponsor / Collaborator

BioAge Labs, Inc.

ACTRN12626000852358

/ Not yet recruitingNot ApplicableIIT

Intraocular Pressure Outcomes with Scleral Indentation Following Intravitreal Injection: A Clinical Crossover Trial in Patients Receiving Routine Intravitreal Anti-VEGF Injections

Start Date03 Aug 2026

Sponsor / Collaborator

The University of New South Wales

100 Clinical Results associated with Pegaptanib sodium

100 Translational Medicine associated with Pegaptanib sodium

100 Patents (Medical) associated with Pegaptanib sodium

446

Literatures (Medical) associated with Pegaptanib sodium

12 Aug 2026·Journal of the American Chemical Society

Nanopore-Based Profiling of PEGylation in Nucleic Acid Therapeutics

Article

Author: Bošković, Filip ; Schmidt, Thieme T. ; Baumberg, Jeremy J. ; Patiño Guillén, Gerardo ; Szostak, Jack W. ; Keyser, Ulrich F.

Abstract:

Nucleic acid therapeutics (NATs), including aptamers, offer effective strategies for programmable and targeted disease treatment. To improve their stability and circulation time, oligonucleotides are often conjugated to hydrophilic polymers, such as polyethylene glycol (PEG). However, current bulk techniques fail to resolve PEG heterogeneity, especially in complex biological environments. Here, we use nanopore sensing to quantify the PEG conjugation efficiency of the FDA-approved RNA aptamer pegaptanib. We assembled DNA nanostructures that bind pegaptanib, and then we used solid-state nanopores to quantify pegaptanib PEGylation. We further assessed pegaptanib PEGylation and stability in a serum background and demonstrated that nanopore sensing resolves PEG moieties of distinct molecular weights within the oligonucleotide conjugates. Single-molecule profiling of polymer-RNA conjugates enables iterative improvements in oligonucleotide design and provides a direct means to assess their stability in complex biological environments, thereby advancing the development of more effective NATs.

01 Jul 2026·Journal of medicine and life

Understanding anti-vascular endothelial growth factor medications: chemical properties, costs, and side effects.

Review

Author: Alhazmi, Shaden ; Alrehaili, Ahlam ; Makhdoum, Hanan ; Alharbi, Khalid ; Aljohani, Ghadi ; Alharbi, Abeer ; Afandi, Rahaf

Vascular endothelial growth factor (VEGF) is an important driver of abnormal retinal neovascularization and increased vascular permeability. VEGF overexpression is associated with a number of retinal conditions, such as diabetic macular edema (DME), and neovascular age-related macular degeneration (nAMD). Anti-VEGF treatments have been the most common for these conditions and have improved vision by reducing abnormal blood vessel formation and leakage. This narrative review addressed the fact that the pharmacological properties, safety profiles, and cost-effectiveness of the currently marketed anti-VEGF intravitreal agents (i.e. bevacizumab, ranibizumab, aflibercept, brolucizumab, pegaptanib, and recently faricimab) differ and therefore, each of these agents, have their own unique molecular structure, target specificity, duration of action in the eye, and systemic circulation, each of which will affect the dosing intervals and treatment burden as well as the safety and adverse events associated with each drug. Aflibercept is a high-binding-affinity decoy receptor and is therefore distinct from faricimab, which is a dual-action (VEGF-A and angiopoietin-2) inhibitor. By contrast, ranibizumab, bevacizumab, brolucizumab, and pegaptanib are anti-angiogenic agents with different VEGF blockade profiles, which ultimately lead to distinct clinical outcomes and pharmacokinetic profiles. While anti-VEGF therapies are highly effective, the outcomes regarding safety, efficacy, and cost depend heavily on the study design and reflect the actual treatment paradigm and continuum of care within the healthcare system. The various attributes of agents should help personalize a patient's treatment approach while also addressing potential challenges related to the safety, efficacy, and longevity of treatment for retinal diseases.

01 May 2026·SLAS Technology

Development and validation of a novel ion-pair hydrophilic interaction liquid chromatography method for the separation and quantification of oligonucleotide therapeutics

Article

Author: Li, Xinjie ; Jiang, Yalin ; Wang, Zhen ; Zhang, Qian

BACKGROUND:

This study developed and systematically optimized an ion-pair hydrophilic interaction liquid chromatography (IP-HILIC) system for oligonucleotide medicine analysis, aiming to the issues of insufficient resolution and prolonged retention times commonly encountered in traditional hydrophilic interaction liquid chromatography (HILIC) and ion-pair reversed-phase liquid chromatography (IP-RPLC). Therefore, this study aimed to optimize and validate a TEAA-based IP-HILIC analytical system for both the effective separation and quantitative analysis of oligonucleotides, including evaluations of linearity, sensitivity, precision, and robustness.

METHODS:

By synthesizing an amino/hexadecyl-bifunctionalized silica matrix and systematically optimizing mobile phase parameters (including ion-pair reagent type and concentration, organic solvent, and buffer pH), a highly efficient separation system was established. To validate the separation efficiency, a 21-mer oligonucleotide Fomivirsen and its truncated impurities (5'-21-1 and 3'-21-1) were synthesized, along with Food and Drug Administration(FDA)-approved Kynamro (20-mer), Macugen (28-mer), and Exondys 51 (30-mer) for method evaluation.

RESULTS:

Experimental results demonstrated that under pH 8.0 conditions, a mobile phase system composed of 50 mM triethylamine acetate (TEAA) and acetonitrile enabled baseline separation of 20-30-mer oligonucleotides with a resolution ≥1.5. Using Fomivirsen impurities (e.g., 5'-21-1 and 5'-21-3) as examples, the retention times were optimized to between 3.76 and 6.76 min, achieving a resolution of 3.82. Acetonitrile shortened the analysis time by 34% compared with methanol, while 50 mM TEAA maintained resolution in the range of 2.58-3.71 and avoided the excessive retention seen at 100 mM, where the peak time extended to 7.57 min.Method validation demonstrated that the method exhibited good linearity (R²>0.999) over the concentration range of 0.05-10 μg/mL, with a limit of detection (LOD) of 0.2 μM and a limit of quantitation (LOQ) of 0.6 μM. The method also showed satisfactory precision (intra-day RSD < 1.5%, inter-day RSD < 2.1%) and was robust against minor variations in mobile phase composition, column temperature, and flow rate. Compared to traditional methods, IP-HILIC demonstrated significantly superior resolution (1.50-2.09) for long-chain oligonucleotides (e.g., 30-mer Exondys 51) over IP-RPLC (1.30) and HILIC (1.20), with better peak symmetry (tailing factor <1.2).

CONCLUSION:

This study provides an systematically optimized and validated analytical platform for the quality control of oligonucleotide medicines, particularly showing significant advantages in the separation of key impurities (e.g., n-1 sequences) for long-chain oligonucleotides (20-30 mer), laying a technical foundation for the precise analysis of hydrophilic biopolymers.

News (Medical) associated with Pegaptanib sodium

09 Apr 2025

·www.businesswire.com

Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment career, Dr. Cunningham has led or co-led financings that contributed to the FDA approval of ten therapeutics, including ophthalmic treatments such as Xiidra®, Rhopressa®, Rocklatan®, Syfovre®, and Izervay®. He previously served as Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, where he played a leadership role in the development of Macugen® (pegaptanib sodium), the first VEGF-A inhibitor approved for neovascular age-related macular degeneration and diabetic macular edema. Prior to Eyetech, Dr. Cunningham held clinical development and licensing roles at Pfizer, focused on central nervous system and ophthalmology assets. “Emmett’s extensive background in science, medicine, and strategic investing, particularly within ophthalmology, adds significant depth to our Board at a time of meaningful momentum for Aviceda,” said Jeffrey Nau, Ph.D., M.M.S., President and Chief Executive Officer of Aviceda Therapeutics. “His unique combination of clinical insight, biopharma operating experience, and investment leadership will be instrumental as we advance AVD-104 into pivotal trials for geographic atrophy and continue to build a leading immunology platform.” “Aviceda is advancing a scientifically compelling approach to immunomodulation that directly addresses longstanding challenges in ophthalmology,” said Dr. Cunningham. “The potential of the HALOS™ platform, beginning with AVD-104, extends beyond current treatment paradigms. I look forward to contributing to the company’s efforts to translate their innovative approaches into meaningful outcomes for patients with serious, underserved diseases.” Dr. Cunningham currently serves on the Boards of Eyconis, Oryon Cell Therapies, Nacuity Pharmaceuticals, and InflammX Therapeutics, and has held board positions at more than a dozen innovative biopharma companies, including Annexon Biosciences (NASDAQ: ANNX), GrayBug Vision (NASDAQ: GRAY), Lumos Pharma (NASDAQ: LUMO), SARcode Biosciences (acquired by Shire), Galera Therapeutics (GRTX) and the SFJ Pharmaceutical Group. He is also the founder and former chairman of the Ophthalmology Innovation Summit (OIS), a long-standing platform that brings together leaders in ophthalmic science, innovation, and investment. Dr. Cunningham is an internationally recognized expert in ocular inflammatory and infectious disease, with more than 400 co-authored publications. He earned an M.D. and M.P.H. in epidemiology and statistics from Johns Hopkins University, and a Ph.D. in neuroscience from the University of California at San Diego for research conducted at The Salk Institute. He completed his ophthalmology residency and fellowship training at UCSF and The Francis I. Proctor Foundation, with additional fellowships in Retina at Moorfields Eye Hospital in London and Public health Ophthalmology at The Dana Center of the Wilmer Eye Institute in Baltimore. He currently teaches at California Pacific Medical Center, serves as an Adjunct Clinical Professor of Ophthalmology at Stanford University, and is a Research Associate at UCSF School of Medicine. About Aviceda Therapeutics and AVD-104 Aviceda is a private, clinical-stage biotechnology company located in Cambridge, MA, with a proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform and a clinical-stage ophthalmic candidate, AVD-104, for the treatment of geographic atrophy secondary to age-related macular degeneration. AVD-104 is an intravitreal glycan-coated nanoparticle with a dual mechanism of action that modulates critical inflammatory cellular and complement pathways through 1) direct deactivation of inflammatory microglia/macrophages’ phagocytic activity and repolarization of these activated microglia/macrophages to their healing state and 2) inhibition of complement cascade amplification. Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including immunology, fibrosis, oncology, and neurology. Visit the company website to learn more about Aviceda Therapeutics and follow the company on LinkedIn and X (formerly Twitter).

Executive ChangeDrug Approval

04 Sep 2024

·www.globenewswire.com

iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs

For immediate release iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs WAVRE, Belgium — 4 September 2024: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the strengthening of its leadership team with the appointment of Richard (Rick) Beckman, M.D., as Chief Medical Officer and member of the Board, and Kristine (Kris) Curtiss as Vice President of Clinical Affairs. Rick’s duties as Chief Medical Officer (CMO) will cross clinical, regulatory, and medical affairs. Additionally, he will be a member of the Board. Rick brings deep insight and experience from his previous roles as a CMO, most recently at Adverum, and has an extensive background in the medical and surgical management of glaucoma as well as in glaucoma pharmaceutical and device development. Based in the US, he will be critical to the successful development of the Company’s clinical programs and will report to the Chief Executive Officer (CEO), Michel Vanbrabant. Kaweh Mansouri, M.D., who is stepping down as CMO to focus on his appointment as Executive Vice President of the World Glaucoma Association, will continue as a consultant to the Company as a Senior Medical Advisor. Kris joins the leadership team as Vice President (VP) of Clinical Affairs with over 20 years of clinical research experience and having held senior positions in biotech, medical device, and large pharma companies. She will lead iSTAR Medical’s clinical organization including its STAR-V trial and will report to the CMO, Rick Beckman. David Stocker, who held the role of VP of Clinical Affairs will return to his previous responsibilities in the commercial organization as VP Sales, Marketing, and Training. Michel Vanbrabant, CEO of iSTAR Medical, commented: “We are delighted to welcome Rick and Kris to our leadership team. Their combined global experience in clinical, regulatory, and medical affairs will be instrumental in guiding the Company towards delivering breakthrough eye care solutions to a greater number of patients in additional global territories. “I want to extend my gratitude to Kaweh for his significant contributions to iSTAR Medical thus far, which has helped us establish a global reputation for MINIject® as a safe and effective treatment option for glaucoma patients. We congratulate him and wish him the best of luck with his role as Executive Vice President of the World Glaucoma Association.” Richard Beckman, M.D., Chief Medical Officer and member of the BoardRick, a board-certified ophthalmologist and fellowship trained glaucoma specialist, is a seasoned professional with extensive experience in the healthcare and biotechnology sectors. He was previously CMO at Adverum Biotechnologies, ReNeuron, as well as Clearside Biomedical. He was formerly the head of the glaucoma therapeutic area at Alcon. Rick is currently the principal at RLB, M.D., Consulting and serves on the Board of OceanZero US. He holds an M.D. from University of Michigan, completing his ophthalmology residency at Henry Ford Hospital, after which he completed a glaucoma fellowship at Massachusetts Eye and Ear Infirmary/Harvard Medical School. Kristine Curtiss, Vice President of Clinical AffairsKris joins the iSTAR Medical team with extensive experience in clinical research and ophthalmology. She was previously VP Clinical Operations at Iveric Bio, Inc., and prior to that she held leadership positions at ophthalmic start-ups including PanOptica, Oraya Therapeutics, and OPKO. During her career, Kris has been a major contributor to 5 successful marketing applications, including Iverzay™ for Geographic Atrophy and Macugen® for exudative Age-related Macular Degeneration. She holds a Bachelor of Science in Chemistry from the University of Delaware and a graduate certificate in Project Management from Rutgers University School of Business. – Ends – For more information Paul van HagenChief Financial Officer, iSTAR Medicalnews@istar-medical.com For mediaICR ConsiliumAmber Fennell, Chris Welsh, Kris LamiSTAR@consilium-comms.com About iSTAR Medical iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject®, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness – and we are aiming to seek market approval in the US. We believe MINIject®’s distinctive tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of potentially leading products such as MINIject® to establish new treatment paradigms in eye care conditions with the highest patient needs. iSTAR Medical is an independent company which entered a strategic partnership with AbbVie (NYSE: ABBV) in July 2022. The collaboration further supports the role of MINIject® in the treatment of glaucoma and accelerates iSTAR Medical’s goal to bring MINIject® to more patients globally while providing AbbVie the opportunity to further expand its diverse eye care portfolio. About MINIject® MINIject® is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. About GlaucomaGlaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.1,2 IOP reduction, through medication or surgery, helps delay disease progression.3 Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs.2,3 Invasive surgery can present risks with irreversible complications and often requires long-term patient management.2,3 MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.2 MINIject® is potentially best-in-class for its promising long-term efficacy and safety. 1 Jonas JB, Aung T, Bourne RR et al. "Glaucoma". Lancet 2017; 390: 2083–932 Market Scope, “2023 Glaucoma Surgical Device Market Report”, July 2023. 3 “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo-bmj-com.libproxy1.nus.edu.sg/content/101/5/73

Executive Change

16 Apr 2024

·www.globenewswire.com

Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

Ophthalmology industry veteran brings 20 years of experience as a life science investor and entrepreneur to Nacuity’s boardFORT WORTH, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and other diseases caused by oxidative stress, today announced the appointment of Emmett T. Cunningham, Jr., M.D., Ph.D., MPH, to its board of directors. Dr. Cunningham is currently a Senior Partner at HealthQuest Capital Management and co-founder and Executive Chairman of Eyconis, Inc., a spinout of Ascendis Pharma created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. “We’re thrilled to welcome Dr. Cunningham to our board of directors,” said Halden Conner, Chairman, CEO and Co-Founder of Nacuity Pharmaceuticals. “His career as a prominent leader in the ophthalmology industry, bridging the business world and ophthalmic innovation, will be a vital asset at this pivotal time for our clinical programs in oxidative stress.” Dr. Cunningham is an ophthalmology industry veteran with over 20 years of experience as a full-time investor and entrepreneur who has led or co-led investments and partnerships in the medical device and biotechnology space that have supported the FDA approval of multiple therapeutics. He is also an internationally recognized specialist in infectious and inflammatory eye disease with over 400 publications. “Nacuity’s approach to treating ophthalmic and non-ophthalmic disorders is both completely novel and tremendously promising,” said Dr. Cunningham. “I look forward to working with the Nacuity team to unlock the broad therapeutic potential of its clinical programs in treating ocular and non-ocular disease.” Prior to HealthQuest and Eyconis, Dr. Cunningham served as a Senior Managing Director at Blackstone, Inc. following that firm’s acquisition of Clarus Ventures in 2018. At Clarus, Dr. Cunningham was a member of the full-time investment team since the firm’s inception in 2006. From 2001 to 2005, Dr. Cunningham was the Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, Inc., where he was part of the leadership team that developed Macugen®, a first-in-class VEGF-A inhibitor for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc. In addition, Dr. Cunningham was the co-founder and chairman of the Ophthalmology Innovation Summit (OIS). He received an M.D. and MPH in epidemiology and statistics from Johns Hopkins University and a Ph.D. in neuroscience from the University of California at San Diego for work done at The Salk Institute. Dr. Cunningham is a member of the board of directors of Galera Therapeutics and Executive Chairman of Eyconis. He serves as Innovator in Residence for Johns Hopkins Technology Ventures (JHTV); as a member of the Biomedical Engineering Advisory Board at Johns Hopkins University; is an advisor to the Byers Center for BioDesign at Stanford University; and serves philanthropically on the Boards of The Alta Foundation and EverythingALS. About Nacuity Pharmaceuticals, Inc. Nacuity Pharmaceuticals, Inc. (https://www.nacuity.com/), is a clinical-stage leader in innovative treatments for diseases produced by oxidative stress. The company’s powerful, targeted therapies aim to attenuate oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has three highly differentiated, first-in-class clinical development programs ongoing in retinitis pigmentosa, cataract and inherited cystinosis. Nacuity has operations in Fort Worth, TX, USA, and Australia, and extensive managerial and scientific domain expertise as well as backing from Foundation Fighting Blindness (https://www.fightingblindness.org/) and its venture arm RD Fund (https://www.retinaldegenerationfund.org). Nacuity Media ContactJulia Clements267.626.1085jclements@6degreespr.com

Executive ChangeAcquisition

100 Deals associated with Pegaptanib sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D05386	Pegaptanib sodium	S01LA03	DB04895

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dystrophy, Macular	Canada	Pfizer Canada ULC	26 Aug 2005
Wet age-related macular degeneration	United States	Bausch & Lomb, Inc.	17 Sep 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Cancer	Phase 3	Finland	Pfizer Inc.	01 Jan 2011
Ovarian Cancer	Phase 3	Spain	Pfizer Inc.	01 Jan 2011
Ovarian Cancer	Phase 3	Sweden	Pfizer Inc.	01 Jan 2011
Ovarian Cancer	Phase 3	United Kingdom	Pfizer Inc.	01 Jan 2011
Macular Edema	Phase 3	Japan	Pfizer Inc.	01 May 2010
Diabetic macular oedema	Phase 3	United States	Pfizer Inc.	01 Sep 2005
Diabetic macular oedema	Phase 3	Australia	Pfizer Inc.	01 Sep 2005
Diabetic macular oedema	Phase 3	Brazil	Pfizer Inc.	01 Sep 2005
Diabetic macular oedema	Phase 3	Canada	Pfizer Inc.	01 Sep 2005
Diabetic macular oedema	Phase 3	Denmark	Pfizer Inc.	01 Sep 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01573572 (CTgov)	Phase 4	Diabetic macular oedema \| Age Related Macular Degeneration \| Retinal Vein Occlusion ... View more	131	pegaptanib sodium injection	avggiivocb(rqwbbprcbn) = mtmbnkvxjy ccrsljszkj (mugrpuxxxf, 175.544) View more	-	14 Oct 2020
NCT00321997 (V.I.S.I.O.N., Pubmed \| Br J Ophthalmol)	Phase 2/3	Age Related Macular Degeneration \| Wet age-related macular degeneration \| Wet Macular Degeneration	221	pegaptanib sodium (Sham injections)	hnspurnrhl(qoapfwhoti) = fswmipenwg odiunsogyt (xxtwlytkuy )	-	01 Nov 2014
NCT00406107 (Pegaptanib for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO), CTgov)	Phase 4	Retinal Vein Occlusion \| Macular Edema	20	pegaptanib sodium (Macugen) (Pegaptanib Sodium 0.3mg (Macugen))	yjuzddvzsz = hnhwgpwuqd mccftqlvxa (jcweohnhdj, lltreodbfc - yohridgzta) View more	-	12 Sep 2014
	Phase 4	Retinal Vein Occlusion \| Macular Edema	20	pegaptanib sodium (Macugen) (Pegaptanib Sodium 1 mg (Macugen))	yjuzddvzsz = daxyrpbhpj mccftqlvxa (jcweohnhdj, qcsniwrnac - lrwgkxgubp) View more	-	12 Sep 2014
NCT01640171 (CTgov)	Not Applicable	Diabetic macular oedema \| Age Related Macular Degeneration \| Retinal Vein Occlusion	57	Proparacaine Hydrochloride+Xylocaine+Tetravisc (Topical Anesthesia 1 Eye, SC 1 Eye)	busmocxpyl = qlvmsdjmda mbbwsltaiq (djthyfywqd, eeblkeualw - xnqvxpfjiv) View more	-	21 Apr 2014
NCT01640171 (CTgov)	Not Applicable		57	Proparacaine Hydrochloride+Tetravisc (Topical Anesthesia)	cjqrsorwoh(fiiajwbebd) = aizzxjvdbc fhdamtwxwo (kzjeoiewwi, tltegboead - siwvygesjp) View more	-	21 Apr 2014
NCT00790803 (CTgov)	Not Applicable	Uveitis \| Macular Edema	5	Pegaptanib (Macugen)	pzecdjjaae = aildzbnwqy vostjohukg (gwamdnlmid, bsaywxbjrb - ermiyytoky) View more	-	26 Sep 2013
NCT01189461 (CTgov)	Phase 3	Diabetic macular oedema	46	Macugen (pegaptanib sodium)	ogjkxdbxfz = hmvpjnsqnz aibnmixhkc (uaqgcwmipo, mvuatmfpth - ukmtypqviv) View more	-	06 Sep 2013
NCT01100307 (CTgov)	Phase 3	Diabetic macular oedema \| Macular Edema	243	pegaptanib sodium	mthehqwxex = kfcbrcrlmw svqhqirevw (pqtjtabcas, hotqundiks - pfamraofyz) View more	-	15 Jul 2013
ARVO2013	Not Applicable	-	30	Pegaptanib	idtfltettb(rugvsvpohx) = jkwrnblafv tsarhstblt (ckopaoyvpx ) View more	Negative	01 Jun 2013
phase II study (ARVO2013)	Phase 2	Proliferative retinopathy with diabetes mellitus	-	Pegaptanib+Progressive PRP	oifthzwmmv(gslbljkwhj) = byvtwcovnp apcdpglyuv (ceboflxmuw )	Positive	01 Jun 2013
phase II study (ARVO2013)	Phase 2	Proliferative retinopathy with diabetes mellitus	-	Pegaptanib (Full PRP)	oifthzwmmv(gslbljkwhj) = qxatttnzpi apcdpglyuv (ceboflxmuw )	Positive	01 Jun 2013
ARVO2013	Not Applicable	Diabetic macular oedema ischemia	30	Pegaptanib	uhjtrfmkfa(ptyubyqaio) = arfliblzvx qhhwsfvjlw (ekuevufrsu ) View more	Negative	01 Jun 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis